Compare VALN & GGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VALN | GGN |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 875.7M | 824.0M |
| IPO Year | N/A | N/A |
| Metric | VALN | GGN |
|---|---|---|
| Price | $10.85 | $5.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $15.75 | N/A |
| AVG Volume (30 Days) | 12.3K | ★ 397.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.26% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.64 | N/A |
| Revenue Next Year | $12.23 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.43 | $3.51 |
| 52 Week High | $12.25 | $3.91 |
| Indicator | VALN | GGN |
|---|---|---|
| Relative Strength Index (RSI) | 67.90 | 52.42 |
| Support Level | $9.95 | $5.51 |
| Resistance Level | $10.40 | $5.74 |
| Average True Range (ATR) | 0.29 | 0.15 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 98.04 | 56.53 |
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
GAMCO Global Gold Natural Resources & Income Trust is a non-diversified closed-end management investment company. Its primary investment objective is to provide a high current income and capital appreciation as its secondary objective. To achieve its objective, the fund may invest majority of its assets in equity securities of companies principally engaged in the gold and natural resources industries. It also intends to earn income through an option planning of writing (selling) covered call options on equity securities in its portfolio.